FIG. 5.
PDC production of IFN-α in response to HIVADA or CpG type A stimulation is significantly reduced during long-term treatment with exogenous IFN-α2A. PDC frequency and absolute numbers (left panel) or response to CpG or ADA (right panel) are shown. Data are from patients with hepatitis C virus infection that were treated with IFN-α2A and ribavirin. PBMC samples were collected prior to the initiation of therapy and at week 8 of therapy, and PDC production of IFN-α was measured with the flow cytometric assay described in the legend for Fig. 1.